Drug discovery in the ubiquitin–proteasome system (original) (raw)

• Pickart, C. M. Back to the future with ubiquitin. Cell 116, 181–190 (2004).
  Article CAS PubMed Google Scholar
• Wilkinson, K. D. Ubiquitin: a Nobel protein. Cell 119, 741–745 (2004).
  CAS PubMed Google Scholar
• Hershko, A., Ciechanover, A. & Varshavsky, A. Basic Medical Research Award. The ubiquitin system. Nature Med. 6, 1073–1081 (2000).
  Article CAS PubMed Google Scholar
• Ang, X. L. & Harper, J. W. Interwoven ubiquitination oscillators and control of cell cycle transitions. Sci. STKE pe31 (2004).
• Moberg, K. H., Bell, D. W., Wahrer, D. C., Haber, D. A. & Hariharan, I. K. Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature 413, 311–316 (2001).
  Article CAS PubMed Google Scholar
• Koh, M. S., Ittmann, M., Kadmon, D., Thompson, T. C. & Leach, F. S. CDC4 gene expression as potential biomarker for targeted therapy in prostate cancer. Cancer Biol. Ther. 5, 78–83 (2006).
  Article CAS PubMed Google Scholar
• Ruffner, H., Joazeiro, C. A., Hemmati, D., Hunter, T. & Verma, I. M. Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc. Natl Acad. Sci. USA 98, 5134–5139 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Ekholm-Reed, S. et al. Mutation of hCDC4 leads to cell cycle deregulation of cyclin E in cancer. Cancer Res. 64, 795–800 (2004).
  Article PubMed Google Scholar
• Gandhi, S. & Wood, N. W. Molecular pathogenesis of Parkinson's disease. Hum. Mol. Genet. 14 (Spec. No. 2), 2749–2755 (2005).
  Article PubMed CAS Google Scholar
• Gasser, T. Genetics of Parkinson's disease. Curr. Opin. Neurol. 18, 363–369 (2005).
  Article CAS PubMed Google Scholar
• Dauer, W. & Przedborski, S. Parkinson's disease: mechanisms and models. Neuron 39, 889–909 (2003).
  Article CAS PubMed Google Scholar
• Vila, M. & Przedborski, S. Genetic clues to the pathogenesis of Parkinson's disease. Nature Med. 10 (Suppl.), S58–S62 (2004).
  Article PubMed CAS Google Scholar
• Tanaka, K., Suzuki, T., Hattori, N. & Mizuno, Y. Ubiquitin, proteasome and parkin. Biochim. Biophys. Acta 1695, 235–247 (2004).
  Article CAS PubMed Google Scholar
• Al-Kuraya, K. et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res. 64, 8534–8540 (2004).
  Article CAS PubMed Google Scholar
• Honda, R., Tanaka, H. & Yasuda, H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420, 25–27 (1997).
  Article CAS PubMed Google Scholar
• Iwakuma, T. & Lozano, G. MDM2, an introduction. Mol. Cancer Res. 1, 993–1000 (2003).
  CAS PubMed Google Scholar
• Nakayama, T. et al. MDM2 gene amplification in bone and soft-tissue tumors: association with tumor progression in differentiated adipose-tissue tumors. Int. J. Cancer 64, 342–346 (1995).
  Article CAS PubMed Google Scholar
• Shieh, S. Y., Ikeda, M., Taya, Y. & Prives, C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91, 325–334 (1997).
  Article CAS PubMed Google Scholar
• Kussie, P. H. et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274, 948–953 (1996).
  Article CAS PubMed Google Scholar
• Montes de Oca Luna, R., Wagner, D. S. & Lozano, G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378, 203–206 (1995).
  Article CAS PubMed Google Scholar
• Li, M. et al. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science 302, 1972–1975 (2003).
  Article CAS PubMed Google Scholar
• Carrano, A. C., Eytan, E., Hershko, A. & Pagano, M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nature Cell Biol. 1, 193–199 (1999).
  Article CAS PubMed Google Scholar
• Hershko, D. et al. Inverse relation between levels of p27(Kip1) and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer 91, 1745–1751 (2001).
  Article CAS PubMed Google Scholar
• Kossatz, U. et al. Skp2-dependent degradation of p27kip1 is essential for cell cycle progression. Genes Dev. 18, 2602–2607 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Nakayama, K. et al. Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication. EMBO J. 19, 2069–2081 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Nakayama, K. et al. Skp2-mediated degradation of p27 regulates progression into mitosis. Dev. Cell 6, 661–672 (2004).
  Article CAS PubMed Google Scholar
• Nijman, S. M. et al. A genomic and functional inventory of deubiquitinating enzymes. Cell 123, 773–786 (2005).
  Article CAS PubMed Google Scholar
• Rubinfeld, B. et al. Stabilization of β-catenin by genetic defects in melanoma cell lines. Science 275, 1790–1792 (1997).
  Article CAS PubMed Google Scholar
• Welcker, M. et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc. Natl Acad. Sci. USA 101, 9085–9090 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Wei, W., Jin, J., Schlisio, S., Harper, J. W. & Kaelin, W. G. Jr. The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell 8, 25–33 (2005).
  Article CAS PubMed Google Scholar
• Adams, J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5, 417–421 (2004).
  Article CAS PubMed Google Scholar
• Burger, A. M. & Seth, A. K. The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur. J. Cancer 40, 2217–2229 (2004).
  Article CAS PubMed Google Scholar
• Orlowski, R. Z. et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. 20, 4420–4427 (2002).
  Article CAS PubMed Google Scholar
• Richardson, P. G. et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348, 2609–2617 (2003).
  Article CAS PubMed Google Scholar
• Richardson, P. G. et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352, 2487–2498 (2005). This paper, and Reference 34, provide analysis of data from clinical trials on the proteasome inhibitor bortezomib indicating that the proteasome inhibitor is superior to high-dose dexamethasone in the treatment of relapsed multiple myeloma.
  Article CAS PubMed Google Scholar
• Nalepa, G. & Wade Harper, J. Therapeutic anti-cancer targets upstream of the proteasome. Cancer Treat. Rev. 29 (Suppl. 1), 49–57 (2003).
  Article CAS PubMed Google Scholar
• Kyle, R. A. & Rajkumar, S. V. Multiple myeloma. N. Engl. J. Med. 351, 1860–1873 (2004).
  Article CAS PubMed Google Scholar
• Pickart, C. M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70, 503–533 (2001).
  Article CAS PubMed Google Scholar
• Hershko, A., Heller, H., Elias, S. & Ciechanover, A. Components of ubiquitin-protein ligase system. Resolution, affinity purification & role in protein breakdown. J. Biol. Chem. 258, 8206–8214 (1983). A landmark study that used affinity chromatography with ubiquitin–sepharose to separate and reconstitute the E1–E2–E3 ubiquitin conjugation system, demonstrating that all three components are required for conjugation of ubiquitin to lysine residues in the substrate.
  Article CAS PubMed Google Scholar
• Ciechanover, A., Elias, S., Heller, H. & Hershko, A. 'Covalent affinity' purification of ubiquitin-activating enzyme. J. Biol. Chem. 257, 2537–2542 (1982).
  Article CAS PubMed Google Scholar
• Ciechanover, A., Elias, S., Heller, H., Ferber, S. & Hershko, A. Characterization of the heat-stable polypeptide of the ATP-dependent proteolytic system from reticulocytes. J. Biol. Chem. 255, 7525–7528 (1980).
  Article CAS PubMed Google Scholar
• Ciechanover, A., Heller, H., Elias, S., Haas, A. L. & Hershko, A. ATP-dependent conjugation of reticulocyte proteins with the polypeptide required for protein degradation. Proc. Natl Acad. Sci. USA 77, 1365–1368 (1980).
  Article CAS PubMed PubMed Central Google Scholar
• Vijay-Kumar, S., Bugg, C. E. & Cook, W. J. Structure of ubiquitin refined at 1. 8 A resolution. J. Mol. Biol. 194, 531–544 (1987).
  Article CAS PubMed Google Scholar
• Chau, V. et al. A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science 243, 1576–1583 (1989).
  Article CAS PubMed Google Scholar
• Gregori, L., Poosch, M. S., Cousins, G. & Chau, V. A uniform isopeptide-linked multiubiquitin chain is sufficient to target substrate for degradation in ubiquitin-mediated proteolysis. J. Biol. Chem. 265, 8354–8357 (1990).
  Article CAS PubMed Google Scholar
• Pickart, C. M. Ubiquitin in chains. Trends Biochem. Sci. 25, 544–548 (2000).
  Article CAS PubMed Google Scholar
• Huang, D. T. et al. A unique E1-E2 interaction required for optimal conjugation of the ubiquitin-like protein NEDD8. Nature Struct. Mol. Biol. 11, 927–935 (2004).
  Article CAS Google Scholar
• Huang, D. T. et al. Structural basis for recruitment of Ubc12 by an E2 binding domain in NEDD8's E1. Mol. Cell 17, 341–350 (2005).
  Article CAS PubMed Google Scholar
• Lois, L. M. & Lima, C. D. Structures of the SUMO E1 provide mechanistic insights into SUMO activation and E2 recruitment to E1. EMBO J. 24, 439–451 (2005). Together with references 47 and 48, this study provided the first structural insight into E1-activating enzymes and how they activate ubiquitin-like proteins. These studies also suggested how different E2s are recognized by divergent ubiquitin-like domains located within the E1 enzyme.
  Article CAS PubMed PubMed Central Google Scholar
• VanDemark, A. P. & Hill, C. P. E1 on the move. Mol. Cell 17, 474–475 (2005).
  Article CAS PubMed Google Scholar
• Ren, R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nature Rev. Cancer 5, 172–183 (2005).
  Article CAS Google Scholar
• Arkin, M. R. & Wells, J. A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nature Rev. Drug Discov. 3, 301–317 (2004).
  Article CAS Google Scholar
• Jones, D., Crowe, E., Stevens, T. A. & Candido, E. P. Functional and phylogenetic analysis of the ubiquitylation system in Caenorhabditis elegans: ubiquitin-conjugating enzymes, ubiquitin-activating enzymes & ubiquitin-like proteins. Genome Biol. 3, 2.1–2.15 (2002).
• Stickle, N. H. et al. pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol. Cell Biol. 24, 3251–3261 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Harper, J. W. Neddylating the guardian; Mdm2 catalyzed conjugation of Nedd8 to p53. Cell 118, 2–4 (2004).
  Article CAS PubMed Google Scholar
• Xirodimas, D. P., Saville, M. K., Bourdon, J. C., Hay, R. T. & Lane, D. P. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 118, 83–97 (2004).
  Article CAS PubMed Google Scholar
• Hatakeyama, S., Yada, M., Matsumoto, M., Ishida, N. & Nakayama, K. I. U box proteins as a new family of ubiquitin-protein ligases. J. Biol. Chem. 276, 33111–33120 (2001).
  Article CAS PubMed Google Scholar
• Zheng, N. et al. Structure of the Cul1–Rbx1–Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature 416, 703–709 (2002). The first structural insight into the cullin-based RING-finger family of ubiquitin ligases. Subsequent studies revealed the structure of related complexes and demonstrate how F-box proteins bind substrates (see also References 102,127,140).
  Article CAS PubMed Google Scholar
• Huang, L. et al. Structure of an E6AP-UbcH7 complex: insights into ubiquitination by the E2-E3 enzyme cascade. Science 286, 1321–1326 (1999).
  Article CAS PubMed Google Scholar
• Petroski, M. D. & Deshaies, R. J. Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol. Cell Biol. 6, 9–20 (2005).
  Article CAS PubMed Google Scholar
• Fang, S., Lorick, K. L., Jensen, J. P. & Weissman, A. M. RING finger ubiquitin protein ligases: implications for tumorigenesis, metastasis and for molecular targets in cancer. Semin. Cancer Biol. 13, 5–14 (2003).
  Article CAS PubMed Google Scholar
• Lane, D. P. & Lain, S. Therapeutic exploitation of the p53 pathway. Trends Mol. Med. 8, S38–S42 (2002).
  Article CAS PubMed Google Scholar
• Balint, E. E. & Vousden, K. H. Activation and activities of the p53 tumour suppressor protein. Br. J. Cancer 85, 1813–1823 (2001).
  Article CAS PubMed Central Google Scholar
• Pavletich, N. P., Chambers, K. A. & Pabo, C. O. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev. 7, 2556–2564 (1993).
  Article CAS PubMed Google Scholar
• Vousden, K. H. & Prives, C. P53 and prognosis: new insights and further complexity. Cell 120, 7–10 (2005).
  CAS PubMed Google Scholar
• Vousden, K. H. & Lu, X. Live or let die: the cell's response to p53. Nature Rev. Cancer 2, 594–604 (2002).
  Article CAS Google Scholar
• Zhang, Z. et al. MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J. Biol. Chem. 279, 16000–16006 (2004).
  Article CAS PubMed Google Scholar
• Wang, H., Nan, L., Yu, D., Agrawal, S. & Zhang, R. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. Clin. Cancer Res. 7, 3613–3624 (2001).
  CAS PubMed Google Scholar
• Prasad, G., Wang, H., Agrawal, S. & Zhang, R. Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme. Anticancer Res. 22, 107–116 (2002).
  CAS PubMed Google Scholar
• Zhang, R., Wang, H. & Agrawal, S. Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities & mechanisms. Curr. Cancer Drug Targets 5, 43–49 (2005).
  Article PubMed Google Scholar
• Karlsson, G. B. et al. Activation of p53 by scaffold-stabilised expression of Mdm2-binding peptides: visualisation of reporter gene induction at the single-cell level. Br. J. Cancer 91, 1488–1494 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Bottger, A. et al. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol. 7, 860–869 (1997).
  Article CAS PubMed Google Scholar
• Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844–848 (2004). This paper identified the first small-molecule inhibitor of the RING-finger protein MDM2, an E3 for p53. The paper demonstrated that the inhibitor blocks binding of p53 to its interaction site on MDM2, thereby blocking its ability to be ubiquitylated.
  Article CAS PubMed Google Scholar
• Rubinstein, L. V. et al. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J. Natl Cancer Inst. 82, 1113–1118 (1990).
  Article CAS PubMed Google Scholar
• Issaeva, N. et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nature Med. 10, 1321–1328 (2004).
  Article CAS PubMed Google Scholar
• Gu, W. & Roeder, R. G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90, 595–606 (1997).
  Article CAS PubMed Google Scholar
• Sakaguchi, K. et al. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12, 2831–2841 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Grossman, S. R. et al. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 300, 342–344 (2003).
  Article CAS PubMed Google Scholar
• Zhu, Q., Yao, J., Wani, G., Wani, M. A. & Wani, A. A. Mdm2 mutant defective in binding p300 promotes ubiquitination but not degradation of p53: evidence for the role of p300 in integrating ubiquitination and proteolysis. J. Biol. Chem. 276, 29695–29701 (2001).
  Article CAS PubMed Google Scholar
• Krajewski, M., Ozdowy, P., D'Silva, L., Rothweiler, U. & Holak, T. A. NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro. Nature Med. 11, 1135–1136 (2005).
  Article CAS PubMed Google Scholar
• Grinkevich, V., Issaeva, N., Hossain, S., Pramanik, A. & Selivanova, G. Reply to 'NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro'. Nature Med. 11, 1136–1137 (2005).
  Article CAS Google Scholar
• Lasne, C., Lowy, R. & Venegas, W. In vitro induction of sister-chromatid exchanges after G0 exposure of human lymphocytes to five naphthofurans. Mutagenesis 4, 27–30 (1989).
  Article CAS PubMed Google Scholar
• Touati, E., Krin, E., Quillardet, P. & Hofnung, M. 7-Methoxy-2-nitronaphtho[2,1-b]furan (R7000)-induced mutation spectrum in the lacI gene of Escherichia coli: influence of SOS mutagenesis. Carcinogenesis 17, 2543–2550 (1996).
  Article CAS PubMed Google Scholar
• Quillardet, P., Boscus, D., Touati, E. & Hofnung, M. DNA damage induced in vivo by 7-methoxy-2-nitronaphtho[2,1-b]-furan (R7000) in the lacI gene of Escherichia coli. Mutat. Res. 422, 237–245 (1998).
  Article CAS PubMed Google Scholar
• Quillardet, P., Michel, V., Arrault, X., Hofnung, M. & Touati, E. Mutagenic properties of a nitrofuran, 7-methoxy-2-nitronaphtho[2,1-b]furan (R7000), in lacI transgenic mice. Mutat. Res. 470, 177–188 (2000).
  Article CAS PubMed Google Scholar
• Bossy-Wetzel, E., Schwarzenbacher, R. & Lipton, S. A. Molecular pathways to neurodegeneration. Nature Med. 10 (Suppl.), S2–S9 (2004).
  Article PubMed CAS Google Scholar
• Dawson, T. M. & Dawson, V. L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 302, 819–822 (2003).
  Article CAS PubMed Google Scholar
• Farrer, M. J. Genetics of Parkinson disease: paradigm shifts and future prospects. Nature Rev. Genet. 7, 306–318 (2006).
  Article CAS PubMed Google Scholar
• Giasson, B. I. & Lee, V. M. Are ubiquitination pathways central to Parkinson's disease? Cell 114, 1–8 (2003).
  Article CAS PubMed Google Scholar
• Kahle, P. J. & Haass, C. How does parkin ligate ubiquitin to Parkinson's disease? EMBO Rep. 5, 681–685 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Nutt, J. G. & Wooten, G. F. Clinical practice. Diagnosis and initial management of Parkinson's disease. N. Engl. J. Med. 353, 1021–1027 (2005).
  Article CAS PubMed Google Scholar
• Tolosa, E., Wenning, G. & Poewe, W. The diagnosis of Parkinson's disease. Lancet Neurol. 5, 75–86 (2006).
  Article PubMed Google Scholar
• Kitada, T. et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605–608 (1998). The authors identified an autosomal recessive juvenile parkinsonism gene located on chromosome 6 as the parkin RING-finger ubiquitin ligase and multiple classes of deletion mutants in the gene. Subsequent studies identified further point mutations which also occur in the RING-finger domain, linking its E3 activity to disease.
  Article CAS PubMed Google Scholar
• Pesah, Y. et al. Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development 131, 2183–2194 (2004).
  Article CAS PubMed Google Scholar
• Greene, J. C., Whitworth, A. J., Andrews, L. A., Parker, T. J. & Pallanck, L. J. Genetic and genomic studies of Drosophila parkin mutants implicate oxidative stress and innate immune responses in pathogenesis. Hum. Mol. Genet. 14, 799–811 (2005).
  Article CAS PubMed Google Scholar
• Haywood, A. F. & Staveley, B. E. Parkin counteracts symptoms in a Drosophila model of Parkinson's disease. BMC Neurosci. 5, 14 (2004).
  Article PubMed PubMed Central Google Scholar
• Yamada, M., Mizuno, Y. & Mochizuki, H. Parkin gene therapy for α-synucleinopathy: a rat model of Parkinson's disease. Hum. Gene Ther. 16, 262–270 (2005).
  Article CAS PubMed Google Scholar
• Shimura, H. et al. Ubiquitination of a new form of α-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293, 263–269 (2001).
  Article CAS PubMed Google Scholar
• Ang, X. L. & Wade Harper, J. (2001). SCF-mediated protein degradation and cell cycle control. Oncogene 24, 2860–2870 (2001).
  Article CAS Google Scholar
• Jin, J. et al. (2001). Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev. 18, 2573–2580 (2001).
  Article CAS Google Scholar
• Latres, E., Chiaur, D. S. & Pagano, M. (2001). The human F box protein β-Trcp associates with the Cul1/Skp1 complex and regulates the stability of β-catenin. Oncogene 18, 849–854 (2001).
  Article CAS Google Scholar
• Wu, G. et al. Structure of a β-TrCP1–Skp1-β-catenin complex: destruction motif binding and lysine specificity of the SCF(β-TrCP1) ubiquitin ligase. Mol. Cell 11, 1445–1456 (2003).
  Article CAS PubMed Google Scholar
• Read, M. A. et al. Nedd8 modification of cul-1 activates SCF(β(TrCP))-dependent ubiquitination of IκBα. Mol. Cell Biol. 20, 2326–2333 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Fero, M. L. et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis & female sterility in p27(Kip1)-deficient mice. Cell 85, 733–744 (1996).
  Article CAS PubMed Google Scholar
• Kiyokawa, H. et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 85, 721–732 (1996).
  Article CAS PubMed Google Scholar
• Nakayama, K. et al. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia & pituitary tumors. Cell 85, 707–720 (1996).
  CAS PubMed Google Scholar
• Bhattacharya, S. et al. SKP2 associates with p130 and accelerates p130 ubiquitylation and degradation in human cells. Oncogene 22, 2443–2451 (2003).
  Article CAS PubMed Google Scholar
• Tedesco, D., Lukas, J. & Reed, S. I. The pRb-related protein p130 is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCF(Skp2). Genes Dev. 16, 2946–2957 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Bornstein, G. et al. Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J. Biol. Chem. 278, 25752–25757 (2003).
  Article CAS PubMed Google Scholar
• Kamura, T. et al. Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation. Proc. Natl Acad. Sci. USA 100, 10231–10236 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Dehan, E. & Pagano, M. Skp2, the FoxO1 hunter. Cancer Cell 7, 209–210 (2005).
  Article CAS PubMed Google Scholar
• Huang, H. et al. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc. Natl Acad. Sci. USA 102, 1649–1654 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Gstaiger, M. et al. Skp2 is oncogenic and overexpressed in human cancers. Proc. Natl Acad. Sci. USA 98, 5043–5048 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Shim, E. H. et al. Expression of the F-box protein SKP2 induces hyperplasia, dysplasia & low-grade carcinoma in the mouse prostate. Cancer Res. 63, 1583–1588 (2003).
  CAS PubMed Google Scholar
• Piva, R. et al. In vivo interference with Skp1 function leads to genetic instability and neoplastic transformation. Mol. Cell Biol. 22, 8375–8387 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Sumimoto, H. et al. Gene therapy for human small-cell lung carcinoma by inactivation of Skp-2 with virally mediated RNA interference. Gene Ther. 12, 95–100 (2005).
  Article CAS PubMed Google Scholar
• Kudo, Y. et al. Small interfering RNA targeting of S phase kinase-interacting protein 2 inhibits cell growth of oral cancer cells by inhibiting p27 degradation. Mol. Cancer Ther. 4, 471–476 (2005).
  Article CAS PubMed Google Scholar
• Jiang, F., Caraway, N. P., Li, R. & Katz, R. L. RNA silencing of S-phase kinase-interacting protein 2 inhibits proliferation and centrosome amplification in lung cancer cells. Oncogene 24, 3409–3418 (2005).
  Article CAS PubMed Google Scholar
• Katagiri, Y., Hozumi, Y. & Kondo, S. Knockdown of Skp2 by siRNA inhibits melanoma cell growth in vitro and in vivo. J. Dermatol Sci. 42, 215–224 (2006).
  Article CAS PubMed Google Scholar
• Hao, B. et al. Structural basis of the Cks1-dependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase. Mol. Cell 20, 9–19 (2005).
  Article CAS PubMed Google Scholar
• Winston, J. T. et al. The SCFβ-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IκBα and β-catenin and stimulates IκBα ubiquitination in vitro. Genes Dev. 13, 270–283 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Rajagopalan, H. et al. Inactivation of hCDC4 can cause chromosomal instability. Nature 428, 77–81 (2004).
  Article CAS PubMed Google Scholar
• Hemann, M. T. et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 436, 807–811 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Kim, W. & Kaelin, W. G., Jr. The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. Curr. Opin. Genet. Dev. 13, 55–60 (2003).
  Article CAS PubMed Google Scholar
• Maxwell, P. H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271–275 (1999).
  Article CAS PubMed Google Scholar
• Ohh, M. et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel-Lindau protein. Nature Cell Biol. 2, 423–427 (2000).
  Article CAS PubMed Google Scholar
• Stebbins, C. E., Kaelin, W. G., Jr. & Pavletich, N. P. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 284, 455–461 (1999).
  Article CAS PubMed Google Scholar
• Hon, W. C. et al. Structural basis for the recognition of hydroxyproline in HIF-1 α by pVHL. Nature 417, 975–978 (2002).
  Article CAS PubMed Google Scholar
• Isaacs, J. S. et al. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 α-degradative pathway. J. Biol. Chem. 277, 29936–29944 (2002).
  Article CAS PubMed Google Scholar
• Isaacs, J. S., Xu, W. & Neckers, L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 3, 213–217 (2003).
  Article CAS PubMed Google Scholar
• Aravind, L. & Koonin, E. V. The U box is a modified RING finger- a common domain in ubiquitination. Curr. Biol. 10, R132–R134 (2000).
  Article CAS PubMed Google Scholar
• Ohi, M. D., Vander Kooi, C. W., Rosenberg, J. A., Chazin, W. J. & Gould, K. L. (2003). Structural insights into the U-box, a domain associated with multi-ubiquitination. Nature Struct. Biol. 10, 250–255.
  Article CAS PubMed Google Scholar
• Hatakeyama, S. & Nakayama, K. I. U-box proteins as a new family of ubiquitin ligases. Biochem. Biophys. Res. Commun. 302, 635–645 (2003).
  Article CAS PubMed Google Scholar
• Xu, W. et al. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc. Natl Acad. Sci. USA 99, 12847–12852 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Zhou, P. et al. ErbB2 degradation mediated by the co-chaperone protein CHIP. J. Biol. Chem. 278, 13829–13837 (2003).
  Article CAS PubMed Google Scholar
• Meacham, G. C., Patterson, C., Zhang, W., Younger, J. M. & Cyr, D. M. The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. Nature Cell Biol. 3, 100–105 (2001).
  Article CAS PubMed Google Scholar
• Imai, Y. et al. CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease & enhances its ubiquitin ligase activity. Mol. Cell 10, 55–67 (2002).
  Article CAS PubMed Google Scholar
• Huibregtse, J. M., Scheffner, M., Beaudenon, S. & Howley, P. M. A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc. Natl Acad. Sci. USA 92, 2563–2567 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Anglesio, M. S. et al. Differential expression of a novel ankyrin containing E3 ubiquitin-protein ligase, Hace1, in sporadic Wilms' tumor versus normal kidney. Hum. Mol. Genet. 13, 2061–2074 (2004).
  Article CAS PubMed Google Scholar
• Talis, A. L., Huibregtse, J. M. & Howley, P. M. The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells. J. Biol. Chem. 273, 6439–6445 (1998).
  Article CAS PubMed Google Scholar
• Cooper, E. M., Hudson, A. W., Amos, J., Wagstaff, J. & Howley, P. M. Biochemical analysis of Angelman syndrome-associated mutations in the E3 ubiquitin ligase E6-associated protein. J. Biol. Chem. 279, 41208–41217 (2004).
  Article CAS PubMed Google Scholar
• Kishino, T., Lalande, M. & Wagstaff, J. UBE3A/E6-AP mutations cause Angelman syndrome. Nature Genet. 15, 70–73 (1997).
  Article CAS PubMed Google Scholar
• Verdecia, M. A. et al. Conformational flexibility underlies ubiquitin ligation mediated by the WWP1 HECT domain E3 ligase. Mol. Cell 11, 249–259 (2003).
  Article CAS PubMed Google Scholar
• Scheffner, M., Huibregtse, J. M., Vierstra, R. D. & Howley, P. M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75, 495–505 (1993). The first demonstration of a HECT-domain ubiquitin ligase and its direct involvement in ubiquitin transfer through a thiol-ester intermediate. Subsequent work (see Reference 138 ) demonstrated that there is a large family of HECT-domain containing proteins that all probably act to promote ubiquitin transfer through a similar mechanism.
  Article CAS PubMed Google Scholar
• Huibregtse, J. M., Scheffner, M. & Howley, P. M. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J. 10, 4129–4135 (1991).
  Article CAS PubMed PubMed Central Google Scholar
• Rolfe, M. et al. Reconstitution of p53-ubiquitinylation reactions from purified components: the role of human ubiquitin-conjugating enzyme UBC4 and E6-associated protein (E6AP). Proc. Natl Acad. Sci. USA 92, 3264–3268 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Gross-Mesilaty, S. et al. Basal and human papillomavirus E6 oncoprotein-induced degradation of Myc proteins by the ubiquitin pathway. Proc. Natl Acad. Sci. USA 95, 8058–8063 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Gewin, L., Myers, H., Kiyono, T. & Galloway, D. A. Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex. Genes Dev. 18, 2269–2282 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Matsuura, T. et al. De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nature Genet. 15, 74–77 (1997).
  Article CAS PubMed Google Scholar
• Buntinx, I. M. et al. Clinical profile of Angelman syndrome at different ages. Am. J. Med. Genet. 56, 176–183 (1995).
  Article CAS PubMed Google Scholar
• Duensing, S. & Munger, K. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int. J. Cancer 109, 157–162 (2004).
  Article CAS PubMed Google Scholar
• Kim, Y., Cairns, M. J., Marouga, R. & Sun, L. Q. E6AP gene suppression and characterization with in vitro selected hammerhead ribozymes. Cancer Gene Ther. 10, 707–716 (2003).
  Article CAS PubMed Google Scholar
• Foster, S. A. & Phelps, W. C. Zn(2+) fingers and cervical cancer. J. Natl Cancer Inst. 91, 1180–1181 (1999).
  Article CAS PubMed Google Scholar
• Harper, D. M. et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367, 1247–1255 (2006).
  Article CAS PubMed Google Scholar
• Mayeaux, E. J., Jr. Harnessing the power of prevention: human papillomavirus vaccines. Curr. Opin. Obstet. Gynecol. 18 (Suppl. 1), S15–S21 (2006).
  Article PubMed Google Scholar
• Lowy, D. R. & Schiller, J. T. Prophylactic human papillomavirus vaccines. J. Clin. Invest. 116, 1167–1173 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Sakamoto, K. M. et al. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc. Natl Acad. Sci. USA 98, 8554–8559 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Sakamoto, K. M. et al. Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation. Mol. Cell Proteomics 2, 1350–1358 (2003).
  Article CAS PubMed Google Scholar
• Zhou, P., Bogacki, R., McReynolds, L. & Howley, P. M. Harnessing the ubiquitination machinery to target the degradation of specific cellular proteins. Mol. Cell 6, 751–756 (2000).
  Article CAS PubMed Google Scholar
• Verma, R. et al. Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. Science 298, 611–615 (2002).
  Article CAS PubMed Google Scholar
• Goldenberg, S. J. et al. Structure of the Cand1-Cul1-Roc1 complex reveals regulatory mechanisms for the assembly of the multisubunit cullin-dependent ubiquitin ligases. Cell 119, 517–528 (2004).
  Article CAS PubMed Google Scholar
• Zheng, J. et al. CAND1 binds to unneddylated CUL1 and regulates the formation of SCF ubiquitin E3 ligase complex. Mol. Cell 10, 1519–1526 (2002).
  Article CAS PubMed Google Scholar
• Cope, G. A. & Deshaies, R. J. COP9 signalosome: a multifunctional regulator of SCF and other cullin-based ubiquitin ligases. Cell 114, 663–671 (2003).
  Article CAS PubMed Google Scholar
• Wei, N. & Deng, X. W. The COP9 signalosome. Annu. Rev. Cell Dev. Biol. 19, 261–286 (2003).
  Article CAS PubMed Google Scholar
• Ambroggio, X. I., Rees, D. C. & Deshaies, R. J. JAMM: a metalloprotease-like zinc site in the proteasome and signalosome. PLoS Biol. 2, E2 (2004).
  Article CAS PubMed Google Scholar
• Cope, G. A. et al. Role of predicted metalloprotease motif of Jab1/Csn5 in cleavage of Nedd8 from Cul1. Science 298, 608–611 (2002). This study identified the machinery required to remove NEDD8 from cullins and demonstrated an important role for NEDD8-removal for the biological activity of SCF complexes.
  Article CAS PubMed Google Scholar
• Verma, R., Oania, R., Graumann, J. & Deshaies, R. J. Multiubiquitin chain receptors define a layer of substrate selectivity in the ubiquitin–proteasome system. Cell 118, 99–110 (2004).
  Article CAS PubMed Google Scholar
• Verma, R. et al. Ubistatins inhibit proteasome-dependent degradation by binding the ubiquitin chain. Science 306, 117–120 (2004).
  Article CAS PubMed Google Scholar
• Schwartz, D. C. & Hochstrasser, M. (2003). A superfamily of protein tags: ubiquitin, SUMO and related modifiers. Trends Biochem. Sci. 28, 321–328.
  Article CAS PubMed Google Scholar